Exact Sciences Corp
NASDAQ:EXAS

  • LAST PRICE
    51.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 51.0000
  • Day Range
    ---
  • 52 Week Range
    50.0900
    100.7700
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
EXAS
Exact Sciences Corp
9.3B
-38.5x
---
UTHR
United Therapeutics Corp
12.2B
13.0x
+8.22%
QGEN
Qiagen NV
10.1B
29.8x
+12.66%
BMRN
Biomarin Pharmaceutical Inc
14.7B
72.9x
---
MEDP
Medpace Holdings Inc
12.2B
40.5x
+35.10%
EXEL
Exelixis Inc
6.1B
32.6x
-21.77%
As of 2024-05-21

Company Information

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Contact Information

Headquarters
5505 Endeavor LaneMADISON, WI, United States 53719
Phone
608-284-5700
Fax
608-284-5701

Executives

Chairman of the Board, President, Chief Executive Officer
Kevin Conroy
Chief Financial Officer
Aaron Bloomer
Executive Vice President - Human Resources
Sarah Condella
Senior Vice President, General Counsel
James Herriott
General Manager - Precision Oncology
Brian Baranick

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$9.4B
Revenue (TTM)
$2.5B
Shares Outstanding
184.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.27
EPS
$-1.32
Book Value
$17.34
P/E Ratio
-38.5x
Price/Sales (TTM)
3.7
Price/Cash Flow (TTM)
---
Operating Margin
-9.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.